CLINICAL PROT OCOL
The Effects of a Digital Customized Healthy Habit Softwar e (Pr o2col Health) on Health-Related 
Habits, Healthspan, and Biological Age
Investigational Pr oduct (if applicable):
  Pro2col
CRO Pr otocol Number:
P083124
IRB Pr otocol Number:
  Pro00081923
Sponsor:
None; Internal Investigation
Version and Date:
Version 1 9/6/2024
1
TABLE OF CONTENTS
1. 
ETHICS 
6
1.1. 
Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) 
6
1.2. 
Ethical Conduct of the Study 
6
1.3. 
Subject Information and Consent 
6
2. 
INVESTIGA TORS AND STUDY ADMINISTRA TIVE 
STRUCTURE 
7
3. 
STUDY OBJECTIVES 
  8
3.1. 
Primary Objective 
  8
3.2. Secondary Objectives   8
3.3 
             Exploratory Objectives   8
4. 
OUTCOMES MEASURE 
  9
4.1. 
Primary Outcomes 
  9
4.2. Secondary Outcomes   9  
4.3. Exploratory Outcomes   9
5. 
INVESTIGA TIONAL PLAN 1
0
5.1. 
Overall Study Design and Plan 1
0
5.2. 
Selection of Study Population 1
0
5.3. 
Inclusion Criteria 1
0
5.3.1 
Exclusion Criteria 1
1
6. 
CONDITIONS
 1
3
6.1.1 
Study 
Administration 1
3
6.2. 
Identity of Experimental Condition 1
3
6.3. 
Identity of Control Condition
 
15
6.4. 
Blinding 1
5
6.5. 
Expected / Unexpected Risk 1
5
6.6. 
Prior and Concomitant Medications and Therapies 
16
7. 
STUDY PROCEDURES 
17
7.1. 
SCREENING
 
 
17
7.2. 
BASELINE TESTING
  
17
7.3. 
INTER VENTION
 
17
7.4. POST -TESTING                                                                                 17
2
7.5. 
Subject W ithdrawal and Early T ermination 
18
7.5.1 
Protocol Deviations 
18
7.5.2 
Status Classification 
18
8. 
ASSESSMENTS 
19
8.1. 
Clinical Evaluations 
19
8.2. 
Assessment of Safety 
19
9. 
ADVERSE EVENT REPOR TING 2
0
9.1. 
Introduction 2
0
9.2. 
Reporting Period 2
0
9.3. 
Definition of an Adverse Event 2
0
9.4. 
Serious Adverse Events 2
1
9.5. 
Severity Assessment 2
1
9.6. 
Causality Assessment 2
2
10. 
STATISTICAL METHODS 
                                                             22
10.1. 
Sample Size Determination 
22
10.2. 
Demographics and Baseline Characteristics 
22
10.3. 
Analyses 
22
10.3.1 
Primary Analysis 
22
10.3.2 
Interim Analysis 
23
10.3.3 
Safety Analysis 
23
11. 
QUALITY CONTROL AND QUALITY ASSURANCE 
23
12. 
ADMINISTRA TIVE REQUIREMENTS 
24
12.1. 
Protocol Amendments and Administrative Changes 
24
12.2. 
Data Handling and Record Keeping 
24
12.3. 
Case Report Forms / Electronic Data Record 
24
12.4. 
Record Retention 
25
13. 
PUBLICA TION OF STUDY RESUL TS 
25
14. 
REFERENCES 
26
APPENDIX 1 METHODOLOGIES FOR STUDY OUTCOMES 
27
3
List of Abbr eviations and Definitions of T erms.
Abbreviation/ Term
Definition
  AE
Adverse Event
  AHA
American Heart Association
BMI
Body Mass Index
CIB/PI
Clinical Investigator Brochure/Package Insert
CRF
Case Report Form
CRO
Contract Research Organization
EOS
End of study
FDA
Food and Drug Administration
GCP
Good Clinical Practice
HIPAA
Health Insurance Portability and Accountability Act
ICF/ICD
Informed consent form/Informed consent document
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
INP
Investigational Nutritional Product
IRB
Institutional Review Board
PHQ-9
Patient Health Questionnaire 9
PI
Principal Investigator
PPP
Per Protocol Population
QA
Quality Assurance
QC
Quality Control
¬Æ
Registered Trademark
SAE
Serious Adverse Event
SF-36
Short Form 36
SOPs
Standard Operating Procedures
USDA
United States Department of Agriculture
4
1. ETHICS
1.1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
It is the responsibility of the investigator to have prospective approval of the study 
protocol, protocol amendments, informed consent forms, and other relevant documents, 
e.g., recruitment materials, if applicable, from the IRB/IEC. All correspondence with the 
IRB/IEC should be retained in the Investigator File (Site Master File). Copies of 
IRB/IEC approvals should be forwarded to the Sponsor .
The only circumstance in which a protocol amendment may be initiated prior to 
IRB/IEC approval is where the change is necessary to eliminate apparent immediate 
hazards to the subjects. In that event, the investigator must notify the IRB/IEC and the 
Sponsor in writing within 5 working days after the implementation.
1.2. Ethical Conduct of the Study
The study will be performed in accordance with the protocol, International Conference on 
Harmonization Good Clinical Practice guidelines (ICH E6-R2) and applicable local 
regulatory requirements and laws.
1.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject 
names on any forms, reports, publications, or in any other disclosures. In case of data 
transfer , Sponsor will maintain high standards of confidentiality and protection of subject 
personal data.
The informed consent form must be agreed to by the Sponsor and the IRB/IEC and must 
be in compliance with ICH GCP , local regulatory requirements, and legal requirements.
The investigator must ensure that each study subject, or his/her legally acceptable 
representative, is fully informed about the nature and objectives of the study and possible 
risks associated with participation. The investigator , or a person designated by the 
investigator , will obtain written informed consent from each subject or the subject's 
legally acceptable representative before any study-specific activity is performed. The 
informed consent form used in this study , and any changes made during the course of the 
study , must be prospectively approved by both the IRB/IEC and the Sponsor before use. 
The investigator will retain the original of each subject's signed consent form.
5
2. INVESTIGA TORS AND STUDY ADMINISTRA TIVE STRUCTURE
Details on the administrative structure of the study (e.g., investigator , coordinating, 
steering committee, administration, monitoring and evaluation committees, institutions, 
statistician, central laboratory facilities, external service provider (ESP or CRO), or
clinical study supply management) will be maintained in the Sponsor ‚Äôs Study Master File 
throughout the study for inclusion in the clinical study report. 
6
3. STUDY OBJECTIVES
3.1. Primary Objective 
‚óè 
The primary objective is to explore the effects of a 4-6-week (28-42 days 
depending on subject availability for last testing day) intervention utilizing a 
novel health application (Pro2col Health) on daily activity , nutritional 
awareness, and numerous health outcomes in overweight but otherwise healthy 
subjects. 
3.2.      Secondary Objectives
‚óè 
To assess subjective indications of depression using the PHQ-9 Scale.
‚óè 
To assess subjective indications of quality of life, using the SF-36 Health Survey .
3.3.     Exploratory Objectives 
‚óè 
Record any adverse event (AE) experienced by study subjects after enrollment in 
the digital application.
7
4. OUTCOMES MEASURE
4.1. 
Primary Outcomes ‚Äì these measur es will be taken at week 0 (pre) and week 7 
(post)
‚óè 
Healthspan
, as assessed via a digital score within the application software. 
‚óè 
Biological Age
, as assessed via an algorithm sourced within the application. 
‚óè 
Lifestyle Risk Factors
, as assessed via questionnaires within the application. 
‚óè 
Energy and V itality
, as assessed via questionnaires within the application. 
‚óè 
Strength and Endurance
, as assessed by performance measures including a timed mile 
walk/run, push-ups to exhaustion, and chair get-ups to exhaustion.
‚óè 
Body Composition
, as assessed via a previously validated digital scale. 
‚óè 
Blood Pr essur e
, as assessed via an electronic blood pressure cuf f. 
‚óè 
Lifestyle Habits
, as assessed by specific interfaces within the application and guided by an 
AI ‚Äúcoach.‚Äù
‚óè 
Daily Steps
, as collected via the Apple Health or Google Fit application on the subject‚Äô s 
pre-existing personal device.
4.2. Secondary Outcomes ‚Äì these measur es will be taken at week 0 (pre) and week 7 
(post) 
‚óè 
Depr ession, 
as assessed by the previously validated PHQ-9 subjective questionnaire. 
‚óè 
Quality of Life, 
as assessed by the previously validated SF-36 subjective questionnaire.
8
5. INVESTIGA TIONAL PLAN
5.1. Overall Study Design and Plan
This is a non-blinded randomized controlled pilot trial conducted over up to 8 weeks. 
Week 0 will involve baseline measurements and enrollment, Weeks 1-6 constitute the 
intervention, and Week 7 to 8 is reserved for post-testing. The study will enroll up to 200 
participants, with a minimum of 50 participants who meet the inclusion criteria, and a 
minimum target of 20 participants completing the study in each group (experimental and 
control).
Participants will be recruited from across the United States using a decentralized 
electronic database. The study will include individuals aged 21-60 with a BMI > 25 
(overweight) and < 35. Additionally , qualified subjects must have current daily activity 
records that show an average daily step count under 5,000. Participants must also be free 
of disease and must own either a personal smartphone device with the Apple Health or 
Google Fit application. Finally , participants must be willing to keep their device with 
them at all times to ensure accurate activity tracking.
Following baseline testing and enrollment in the study , participants will be randomly 
assigned to either the control (CON) or experimental (PRO) group. The control group 
will receive subject-facing materials depicting current general activity recommendations 
as published by the American Heart Association (AHA) and current dietary guidelines 
provided by the United States Department of Agriculture (USDA). The experimental 
group will be enrolled in the Prime Health Technologies software (Pro2col), which 
provides a digital diagnostic score to calculate healthspan and biological age, along with 
AI and group community-based coaching dynamics. Subjects will be assigned a 6 week 
progressive protocol targeting improvements in daily activity levels, nutritional 
awareness, and overall lifestyle risk factors. Both groups will then be monitored by study 
staff throughout the duration of the intervention period with post-testing taking place 
following the last week of the experiment.
Due to the remote nature of subject recruitment, no in-person facility visits are required 
for participants. 
5.2. Selection of Study Population
The following eligibility criteria are designed to select subjects for whom protocol 
requirements are considered appropriate. All relevant medical and non-medical 
conditions should be taken into consideration when deciding whether this protocol is 
suitable for a particular subject.
5.2.1  Inclusion Criteria
‚óè 
Male or female, aged 21-60 years.
‚óè 
A BMI categorized as overweight (‚â• 25) but not stage II obesity (‚â§ 35)
‚óè 
Daily steps < 5,000.
9
‚óè 
Ownership of a smartphone device with either the Apple Health or Google Fit 
application.
‚óè 
Willingness to carry their phone in their pocket or on their person at all times to track 
steps during study . 
‚óè 
Willing to download the Pro2col application and connect it with either the Apple 
Health or Google Fit application.
‚óè 
Willingness to complete physical tasks including a timed one-mile walk/run, regular 
or modified push-ups to exhaustion, and chair get-ups to exhaustion.
‚óè 
For the experimental group, subjects must be willing to follow the application 
protocol which is laid out later in this document. 
‚óè 
Able to read, understand, sign and date the informed consent document (English only)
‚óè 
Able and willing to comply with the scheduled visit(s) and study requirements.
5.2.2 Exclusion Criteria
Subjects presenting any of the following will not be included in the study:
‚óè 
Currently taking (within the past 30 days) ergogenic dietary supplements 
including, creatine, protein, amino acids, or stimulants other than caffeine 
(yohimbe, ephedrine, etc.)
‚óè 
Currently taking performance enhancing drugs (testosterone or other 
anabolic-androgenic steroids), human growth hormone, insulin, etc.
‚óè 
History or current malignancy
‚óè 
Receiving chemotherapy agents or radiation treatments
‚óè 
Musculoskeletal disease (muscular dystrophy , arthritis, etc.)
‚óè 
Recent (<3-months) musculoskeletal injuries
‚óè 
BMI < 25 or > 35 kg/m
2
‚óè 
Diagnosis of a terminal illness
‚óè 
Use of prescription medications that influence body composition (i.e., 
prescription hormone therapies, etc.)
‚óè 
History of alcohol abuse
‚óè 
History or current drug abuse
‚óè 
History or current diagnosis of depression.
‚óè 
History or current diagnosis of suicidal thoughts/ideation.
‚óè 
A score of ‚â• 10 arbitrary units on the PHQ-9 during baseline testing.
‚óè 
History or current cigarette smoke (including vaping) within the past 14 days from 
the screening visit
‚óè 
Insulin-dependent diabetes and/or metformin use
‚óè 
Chronic kidney or liver disease 
‚óè 
Has significant concurrent illnesses (controlled or uncontrolled), such as diabetes, 
lupus, epilepsy , or cardiac disorders, hepatitis B/C, HIV , serious mental health illness 
such as dementia or schizophrenia; psychiatric hospitalization in the past two years, 
10
or other , which in the opinion of the investigator , such conditions might be 
aggravated as a result of treatment
‚óè 
The investigator feels that for any reason the subject is not eligible to participate 
in the study
‚óè 
History of uncontrolled cardiovascular disease (i.e., myocardial infarction, 
hypertension, hypercholesterolemia, peripheral vascular disease, other)
‚óè 
Developmental disability or cognitive impairment that would preclude adequate 
comprehension of the informed consent form and/or ability to follow study subject 
requirement and/or record the necessary study measurements
‚óè 
A family member of the investigator or an employee of the investigator
‚óè 
Participation in any other investigational study within 30 days prior to consent.
11
6. CONDITIONS
6.1. Study Administration
All study activities will be performed under the supervision of the investigator in 
accordance with the protocol requirements, and with adherence to Good Clinical 
Practices (GCP) and International Conference on Harmonization (ICH E6 R2).
Only study subjects who signed the informed consent form and meet all entry criteria 
will be enrolled and randomly assigned to a study group.
6.2. Identity of Experimental Condition 
The Experimental Condition involves the use of a novel smartphone application. This 
application provides a digital diagnostic score to calculate healthspan and biological age, 
along with AI and group community-based coaching dynamics. Subjects will be 
assigned a 4-6-week (28-42 days depending on subject availability for last testing day)  
progressive protocol designed to implement lifestyle changes and solidify adherable 
practices including the following:
‚óè 
Daily practice of intermittent fasting, eating within a time restricted eating 
window ranging from 8 to 12 hours. 
‚óè 
Increased daily steps.
‚óè 
Increased awareness of hydration practices.
‚óè 
Journaling
‚óè 
Adherence to a lower carbohydrate, higher -protein diet.
‚óè 
Improved exercise habits.
‚óè 
Stress management 
‚óè 
Sleep habits 
‚óè 
Improved lifestyle risk factors, like smoking and alcohol intake 
The above factors are individualized based on subject responses to questionnaires within 
the application. An AI-based coach and application algorithms will then send users push 
notifications to improve adherence to their new lifestyle factors as well as provide 
feedback for their logged data entries. Specifically , the application users will be required 
to connect the Pro2col application with either the Apple Health or Google Fit application 
so that necessary data can be transmitted between these applications without user input. 
The application creates a personalized protocol by using responses from the embedded 
health questionnaire to establish baseline figures that the user will improve upon. For 
example, if a user reports walking between 4,001-5,000 steps daily , their program will 
start them at 4,000 steps in week 1, gradually increasing each week until they reach the 
program's goal (e.g., 10,000 steps). Below are the key elements used to generate an 
individualized protocol, with specific goals for this user:
Steps Goal
: 10,000 Steps
12
Incremental Approach: Starting from the user's baseline, steps will gradually increase 
each week to reach the target of 10,000 steps over a 4-6-week period (28-42 days 
depending on subject availability for the last testing day).
Example:
Week 1: Starting at the baseline (e.g., 4,000 steps)
Week 2: 5,200 steps
Week 3: 6,400 steps
Week 4: 7,600 steps
Week 5: 8,800 steps
Week 6: 10,000 steps
Calorie Goal
: Moderate Fat Loss
Caloric intake will be reduced on average by 250 calories from basal calorie needs.
Hydration Goal
: Subjects will have a target water consumption goal of 10 Cups of 
Water
Incremental Approach: Starting from the user's baseline (e.g., 5 cups), water intake will 
increase each week until reaching 10 cups over 6 weeks.
Example:
Week 1: 5 cups
Week 2: 6 cups
Week 3: 7 cups
Week 4: 8 cups
Week 5: 9 cups
Week 6: 10 cups
Eating W indow
: 8 Hours
Incremental Approach: The eating window will decrease each week until it reaches an 
8-hour window over 6 weeks.  For example if they are currently eating 16 hours per day 
(for example 6 am to 10 pm), we would modify as such:
Example:
Week 1: 16-hour eating window
Week 2: 14-hour eating window
13
Week 3: 12-hour eating window
Week 4: 10-hour eating window
Week 5: 9-hour eating window
Week 6: 8-hour eating window
Subjects will also be awarded with points within the application for hitting their goal. 
6.3. Identity of Contr ol Condition
Subjects randomly enrolled in the control group will be given materials published by 
the American Heart Association (AHA) and United States Department of Agriculture 
(USDA). The AHA flyer is linked 
her e
 and the USDA booklet is linked 
her e
.
6.4. Blinding
Study of ficials nor participants will be blinded to study conditions.
6.5. Expected / Unexpected Risk
Risks or side ef fects associated with physical fitness programs:
‚óè 
Musculoskeletal injury
‚óè 
Fatigue
‚óè 
Shortness of Breath
‚óè 
Light-headedness or Dizziness
‚óè 
Fainting
Risks or side ef fects associated with intermittent fasting:
‚óè 
Fainting
‚óè 
Dizziness
‚óè 
Hunger
   Risks or side ef fects associated with low carbohydrate diets:
‚óè 
Fainting
‚óè 
Dizziness
‚óè 
Hunger
‚óè 
Fatigue
14
General Statement:
Although no immediate risks or side effects are anticipated for this study , all aspects of 
this clinical investigation will be conducted under the direct supervision and oversight of 
the investigator and designated study staf f. Adverse events whether spontaneous, or self- 
reported, will be collected and analyzed.
6.6. Prior and Concomitant Medications and Therapies
Subjects must abstain from exclusionary procedures/medications/therapies as listed under 
the Exclusion Criteria for the duration of the study , and prior to the study relative to 
certain Exclusion Criteria.
15
7. STUDY PROCEDURES
Study procedures as described in this section are depicted in the schedule of study visits 
of Appendix 1. Methodologies for study outcomes are described in Appendix 1.
7.1. SCREENING 
Subjects who signed the informed consent form will have the following assessments 
performed:
‚óè 
Inclusion and exclusion criteria
‚óè 
Medical and medication history
‚óè 
Demographic and baseline characteristics
Subjects who meet all required entry criteria will be enrolled in the study and will be 
assigned a 
subject No./ID 
in the 100 series starting with 
‚Äú101‚Äù 
and continuing in 
sequential order until enrollment is met.
Enrolled subjects will be scheduled for a remote consultation with a member of the study 
staff to go over the details of the study , their condition assignment, and all related 
materials and procedures for the study .
7.2. BASELINE TESTING 
Subjects who continue to be eligible for this study will then complete baseline testing. 
Subjective questionnaires will be provided to assess items such as current activity levels, 
nutrition habits, and lifestyle factors related to health and wellness. Enrolled and 
randomized subjects will also receive a blood pressure cuff and digital scale to record 
blood pressure and bodyweight/body composition, respectively . Moreover , subjects will 
complete electronic calculations to estimate their healthspan and biological age. Finally , 
subjects will perform three physical fitness tests, including:
‚óè 
Timed one mile walk/run
‚óè 
Push-ups (or modified push-ups for women) to exhaustion
‚óè 
Chair get-ups to exhaustion
7.3. INTER VENTION 
Subjects will follow their assigned condition for 6 weeks. Subjects in the control group 
will be monitored by study staff but otherwise uninstructed in regard to activity and 
nutrition. Their adherence to the provided educational materials is entirely up to them. 
The experimental group will be initiated into a 4-6-week (28-42 days depending on 
subject availability for the last testing day)  progressive protocol on the Pro2col app. 
They will receive daily updates, notification, and education regarding healthy habits 
such as exercise, hydration, and improved nutrition practices. An AI coach will be 
responsible for providing instructions and feedback to all application users.
7.4. POST -TESTING
16
Subjects who complete the 4-6-week (28-42 days depending on subject availability for 
last testing day) intervention and continue to be eligible for this study will then complete 
post testing. Subjective questionnaires will be provided to assess items such as current 
activity levels, nutrition habits, and lifestyle factors related to health and wellness. 
Enrolled and randomized subjects will also receive a blood pressure cuff and digital 
scale to record blood pressure and bodyweight/body composition, respectively . 
Moreover , subjects will complete electronic calculations to estimate their healthspan and 
biological age. Finally , subjects will perform three physical fitness tests, including:
‚óè 
Timed one mile walk/run
‚óè 
Push-ups (or modified push-ups for women) to exhaustion
‚óè 
Chair get-ups to exhaustion
Finally , upon completion of the study (or early withdrawal), subjects will be directed to 
delete the investigational application from their smart device, and no further data will be 
collected.
 
7.5. Subject W ithdrawal and Early T ermination
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn at any time at the discretion of the investigator or Sponsor for safety , 
behavioral, or administrative reasons. Every effort should be made to document the 
subject outcome, if possible. The investigator should inquire about the reason for 
withdrawal, request the subject return for a final visit, and if applicable, follow-up with 
the subject regarding any unresolved adverse events.
If the subject withdraws from the study and also withdraws consent for disclosure of 
future information, no further evaluations will be performed, and no additional data will 
be collected. The Sponsor may retain and continue to use any data collected before such 
withdrawal of consent.
7.6.1.        Pr otocol Deviations
Protocol deviations will be tracked and managed during the conduct of the study . A 
protocol deviation is defined as a non-conformance from the protocol which occurs at 
any time during the conduct of the study . Exceptions will not be granted by the Sponsor 
for any planned or unplanned deviation. All protocol deviations will be tracked.
7.6.2     Status Classification
Classification
Criteria
Screen Failure
Signs the ICD but does not meet entry criteria or withdraws prior to 
Baseline Testing
Enrolled
Signs the ICD and met all inclusion/exclusion criteria
Initiated
Signs the ICD and successfully completes Baseline Testing
17
Discontinued/Withdrawal
Signed the ICD but does not successfully complete the Intervention
Completed
Signs the ICD and successfully completes the Intervention and 
Post-Testing
18
8. ASSESSMENTS
8.1. Clinical Evaluations
The following clinical evaluations will be conducted during the study review:
‚óè 
Medical and Medication History 
‚Äì An assessment of the subject‚Äô s health status 
prior to enrollment to ascertain appropriateness for study participation based on 
inclusion/exclusion criteria.
‚óè 
Adverse Event Reporting ‚Äì 
Investigator examination of the subject and notation 
of any observations made by the study investigator of a potential adverse event.
8.2. Assessment of Safety
Self-reported and observed adverse events.
19
9. ADVERSE EVENT REPOR TING
9.1. Introduction
All observed or volunteered adverse events regardless of treatment group or suspected 
causal relationship to the INP(s) will be reported as described in the following sections.
For all adverse events, the investigator must pursue and obtain information adequate both 
to determine the outcome of the adverse event and to assess whether it meets the criteria 
for classification as a serious adverse event requiring immediate notification to the 
Sponsor or its designated representative. For all adverse events, sufficient information 
should be obtained by the investigator to try to determine the causality of the event. For 
adverse events with a suspected causal relationship to the experimental product, 
follow-up by the investigator is required until the event or its sequel resolve or stabilize at 
a level acceptable to the investigator , and Sponsor concurs with that assessment.
9.2. Reporting Period
Serious adverse events 
require immediate notification within 
24 hours 
to the IRB and 
its designated project manager . When reporting a serious adverse event, the investigator 
or designee completes the SAE form with as much information as possible however , at a 
minimum the Subject ID, Name of INP , SAE, and Name of person reporting the event. 
All adverse events (serious and non-serious) must be collected on the subject‚Äô s case 
report form (CRF) from the time the subject signed informed consent through the last 
subject visit.
9.3. Definition of an Adverse Event
An adverse event is any untoward medical occurrence in a clinical investigation 
associated with the use of an investigational product in human subjects. The event need 
not necessarily have a suspected causal relationship with the treatment or usage.
Examples of adverse events include but are not limited to:
‚óè 
Clinically significant symptoms and signs
‚óè 
Changes in physical examination findings
20
‚óè 
Hypersensitivity
Additionally , they may include the signs or symptoms resulting from:
‚óè 
Product misuse
‚óè 
Product dependency
‚óè 
Extravasation
‚óè 
Study related procedure (e.g., resistance training protocol)
9.4. Serious Adverse Events
A medical device adverse event is serious when both of the following criteria are 
fulfilled:
‚óè 
The event involves patient/subject/consumer contact
‚óè 
The event results in:
‚àí
 
Death
‚àí
 
Serious deterioration in state of health. This includes:
o
 
Life-threatening illness or injury
o
 
Permanent impairment of a body function
o
 
Permanent damage to a body structure
‚àí
 
Requires medical or surgical intervention to prevent permanent 
impairment of a body function or permanent damage to a body structure
‚àí
 
Requires inpatient hospitalization or prolongation of 
existing hospitalization
9.5. Severity Assessment
If required on the adverse event case report forms, the investigator will use the 
adjectives MILD, MODERA TE, or SEVERE to describe the maximum intensity of 
the adverse event. For purposes of consistency , these intensity grades are defined as 
follows:
MILD
Does not interfere with the subject's usual function.
MODERA TE
Interferes to some extent with the subject's usual function.
SEVERE
Interferes significantly with the subject's usual function.
Note the distinction between the severity and the seriousness of an adverse event. A 
severe event is not necessarily a serious event. For example, a headache may be severe 
(interferes significantly with the subject's usual function) but would not be classified 
21
serious unless it met one of the criteria for serious adverse events, listed above.
22
9.6. Causality Assessment
The investigator ‚Äôs assessment of causality must be provided for all adverse events 
(serious and non-serious). An investigator ‚Äôs causality assessment is the determination of 
whether there exists a reasonable possibility that the INP caused or contributed to an 
adverse event. If the investigator ‚Äôs final determination of causality is unknown and the 
investigator does not know whether or not INP caused the event, then the event will be 
handled as ‚Äúrelated to INP‚Äù for reporting purposes. If the investigator's causality 
assessment is "unknown but not related to INP", this should be clearly documented on 
study records.
In addition, if the investigator determines a serious adverse event is associated with study 
procedures, the investigator must record this suspected causal relationship in the source 
documents and CRF, as appropriate, and report such an assessment in accordance with 
the serious adverse event reporting requirements, if applicable.
10. 
STATISTICAL METHODS 
10.1. Sample Size Determination
The targeted sample size of 50 participants was determined by the Sponsor based on a 
meta-analysis involving 206,873 participants (Staiano et al., 2024). This analysis 
demonstrated that digital health interventions led to improvements in physical activity 
(+1,329 steps/day), reduced sedentary behavior (‚àí7 hours/week), and increased 
vigorous exercise (+1 hour/week). Using these values, we conducted a power analysis, 
which identified an effect size difference of 0.8 between the control and experimental 
groups for average changes in habits like daily steps. This analysis confirmed that a 
sample size of 50 subjects would be suf ficient.
https://trialsjournal.biomedcentral.com/articles/10.1 186/s13063-015-0950-4
 
10.2. Demographics and Baseline Characteristics
Demographic information will include age, gender , height, weight, BMI, race, and 
ethnicity .  Baseline characteristics, including health data, subjective questionnaires, and 
anthropometrics will be summarized by treatment. 
10.3. Analyses
10.3.1        Primary Analysis
Descriptive statistics will be reported including mean, median, minimum and maximum 
values, standard deviation, and 95% confidence intervals of the mean. All outcome 
measure data will be reported as mean ¬± standard deviation (SD). Relative and absolute 
changes between groups for all outcomes will be reported and analyzed for statistical 
significance using paired 
t
 tests. Additionally , effect sizes will be calculated as Cohen‚Äô s 
d
g
 
23
for between-subjects analyses as the difference between group means divided by the 
pooled standard deviation times a correction factor [1]. Statistical significance will be set 
at 
p 
< 0.05 and all analyses will be performed using SPSS V ersion 28.0.
Cohen‚Äô s 
d
g
 = 
  ùëã
ùê∫ùëüùëúùë¢ùëù ùê¥ ‚àí ùëã
ùê∫ùëüùëúùë¢ùëù ùêµ
( )
ùëÜùê∑
ùëùùëúùëúùëôùëíùëë
 √ó (1 ‚àí3
4 √ó ùëÅ1+ùëÅ2 ( ) ‚àí 9 )
10.3.2       Interim Analysis
There will be no interim analysis.
10.3.3       Safety Analysis
All safety analyses and summaries will be based on the Safety population. The number 
and percentage of subjects reporting AEs during the study will be tabulated and 
summarized. Subjects experiencing serious adverse events, treatment-related adverse 
events, and discontinuation from the study due to adverse events will also be 
summarized. Treatment-related adverse events will include events marked as being at 
least possibly or probably related to the study dose. Adverse events will be presented 
by severity and by relation to treatment. Enrollment status with respect to number of 
subjects enrolled, completed, lost-to-follow and discontinuation regardless of reason 
will be presented. All adverse events and concomitant medications will be presented in 
listings.
11. QUALITY CONTROL AND QUALITY ASSURANCE
During study conduct, the Sponsor or its agent will conduct periodic monitoring reviews 
(in person or remote) to oversee the progress of the clinical trial and to ensure that it is 
conducted, recorded, and reported in accordance with the protocol, Standard Operating 
Procedures (SOPs) as applicable, Good Clinical Practice (GCP), and the applicable 
regulatory requirement(s).
The Sponsor representative may review source documents to confirm that the data 
recorded on CRFs/eCRF is accurate. The investigator and institution will allow 
Sponsor ‚Äôs representative or its agents, and appropriate regulatory authorities, direct 
access to source documents to perform this verification.
The study site may be subject to review by the institutional review board 
(IRB)/independent ethics committee (IEC), and/or to quality assurance audits performed 
by Sponsor , and/or to inspection by appropriate regulatory authorities.
It is important that the investigator(s) and their relevant personnel are available during 
any in-person monitoring visits and possible audits or inspections, and that sufficient 
time is devoted to the process.
24
12. ADMINISTRA TIVE REQUIREMENTS
12.1. Protocol Amendments and Administrative Changes
Amendments and administrative changes are not to be made to this protocol without 
consultation with and the agreement of the Sponsor . The investigator and Sponsor should 
discuss amendment or administrative change. If agreement is reached, such amendment 
or administrative change will be developed in writing by the Sponsor and submitted to 
the investigator .
The investigator will be responsible for ensuring that all protocol amendments are 
approved in writing by the appropriate IRB or IEC before the institution of the changes 
specified in the amendment (except when necessary to eliminate an immediate hazard to 
the subjects). The investigator will also ensure that the Sponsor receives a copy of the 
written IRB or IEC approval of these changes.
The investigator will be responsible for ensuring that the IRB or IEC receives written 
notification of all administrative changes to the protocol prior to institution of the 
specified changes. The investigator will ensure that the Sponsor receives a copy of these 
written notifications.
12.2. Data Handling and Record Keeping
The investigator will document all study related procedures directly on the source record 
or medical chart as the primary source of data collection. Study related information/data 
points required by the sponsor for analysis will be transcribed by the investigator or 
designee from the source record, onto the CRF/eCRF (data collection tool) for this study 
using good documentation practices.
In some instances, the sponsor will provide a CRF template for use as the primary source 
of data collection.
The investigator is encouraged, however , not required to maintain additional source 
records on matters respective to the subject‚Äô s safety and wellbeing not already captured 
on the CRFs/eCRF or source template.
Black or blue ink must be used on all data collection requirements. All errors and 
omissions must be crossed out by means of a single line, and the date and initials of 
the correction or addition of correct information must be provided. Use of white-out or 
write-overs will not be permitted. All study related records will be kept in a secure and 
locked location and shall only be accessible to the assigned study personnel during the 
conduct of the study , and to the regulatory authorities in the event of an inspection.
All raw and analyzed data files will be stored electronically on a private Google Drive 
folder that is accessible only to study staff. This folder is password protected and 
requires permission for outside entities to access its files.
12.3. Case Report Forms / Electr onic Data Record
As used in this protocol, the term case report form (CRF) should be understood to refer to 
either a paper form or an electronic data record or both, depending on the data collection 
25
method used in this study .
A CRF is required and should be completed for each enrolled subject. The completed 
original CRFs are the sole property of the sponsor and should not be made available in
26
any form to third parties, except for authorized representatives of the sponsor or 
appropriate regulatory authorities, without written permission from the sponsor .
It is the investigator's responsibility to ensure completion, review and approve all CRFs. 
CRFs must be signed by the investigator or by an authorized staff member . These 
signatures serve to attest that the information contained on the CRFs is true and accurate.
At all times, the investigator has final personal responsibility for the accuracy and 
authenticity of all clinical and laboratory data entered on the CRFs. In cases where the 
source documents are the hospital or the physician's chart, the information collected on 
the CRFs must match those charts.
12.4. Record Retention
To enable evaluations and/or audits from regulatory authorities or the Sponsor , the 
investigator agrees to keep records including the identity of all participating subjects 
(sufficient information to link records, e.g., CRFs and hospital records), all original 
signed informed consent forms, copies of all CRFs, serious adverse event forms, source 
documents, and detailed records of treatment disposition. The records should be retained 
by the investigator according to ICH guidelines, local regulations, or as specified in the 
Clinical Study Agreement, whichever is longer .
If the investigator relocates, retires, or for any reason withdraws from the study , the 
Sponsor should be prospectively notified of the event, and the location of study records.
The study records must be transferred to an acceptable designee, such as another 
investigator , another institution, or to the Sponsor .
13. PUBLICA TION OF STUDY RESUL TS
Publication of study results by the investigator is discussed in the Clinical Study 
Agreement, as appropriate. Results from this study may be published in the form of oral 
or written presentations at scientific meetings or as one or more peer-reviewed journal 
articles, with Sponsor ‚Äôs prior approval, otherwise shall be kept strictly confidential. In 
these cases, no information on individual subjects will be revealed.
27
14. REFERENCES
M., Staiano, A.E. et al. A systematic umbrella review and meta-meta-analysis of eHealth and mHealth interventions 
for improving lifestyle behaviors. npj Digit. Med. 7, 179 (2024).
28
APPENDIX 1. METHODOLOGIES FOR STUDY OUTCOMES. 
Healthspan
A subject‚Äô s healthspan will be calculated using a proprietary algorithm housed within the 
prime health application. Briefly , subjects will answer a number of questions regarding their 
daily health habits, activities, and attitudes. These data will then be placed into a 
mathematical equation that uses data and statistics from numerous published studies 
regarding longevity and mortality risk. The outcome number is a subject‚Äô s estimated 
‚ÄúHealthspan,‚Äù which describes their remaining healthy and active years of life. Importantly , 
this number can increase or decrease based on a subject‚Äô s reported lifestyle changes at the 
end of the intervention period.
Biological Age
The subject‚Äô s biological age will be estimated using the same proprietary formula used to 
estimate Healthspan. Briefly , biological age is dif ferent from chronological age, which 
simply reflects the number of years an individual has spent on Earth. Biological age, on the 
other hand, takes healthy lifestyle factors into account that may prematurely age individuals 
past their chronological age. Conversely , active and healthy users may find that their 
biological age is lower than their chronological age.  Importantly , this number can increase 
or decrease based on a subject‚Äô s reported lifestyle changes at the end of the intervention 
period.
Lifestyle Risk Factors
These risk factors are assessed by a number of questions pertaining to lifestyle habits that 
the subject must answer when enrolling in the application. As also extracted from the 
questionnaire. 
Energy and V itality 
These outcome measures are subjective reports based on subject responses to specific 
questions within the application‚Äô s questionnaires.
Strength and Endurance
Application users will be required to perform three objective performance tests to get 
accurate estimates of their healthspan and biological age. These performance tests include:
Upper Body Str ength
: Upper body strength will be assessed using the push-ups to failure 
protocol. Users will be instructed via the application on correct form and technique for 
push-ups specific to their gender . They will then perform as many push-ups as possible 
before reaching concentric muscle failure. This number will be reported to assess their 
upper body strength.
Endurance
: Endurance will be assessed using a one mile walk time. Subjects will perform 
this assessment at their own determined pace, which is obviously restricted by their physical 
ability . Running is allowed, but not all subjects will be able to run the full mile. Thus, 
walking is allowed in this assessment.
Lower Body Str ength
: Lower body strength will be assessed by chair get-ups to concentric 
muscle failure. Briefly , subjects must use a chair or a related sturdy surface that reaches the 
height of their patella. They must fully sit and return to start for each repetition. They will 
29
continue to perform get-ups to concentric muscle failure. This number will be reported to 
assess their lower body strength.
Body Composition
Body composition will be measured using a previously validated digital scale (RENPHO 
Smart Scale ) that will be delivered to participants upon enrollment in the study . The scale 
uses bioelectrical impedance to estimate body composition. This involves a low level 
electrical current being sent through the body; the user cannot feel, hear , or otherwise sense 
this electrical current. The rate at which the current passes through the body is then input 
into an algorithm to estimate body composition based on known electrical current rates in 
human body tissue.
Body composition will also be estimated by questions embedded within the application and 
a corresponding algorithm. 
Blood Pr essur e 
Blood pressure will be measured using a previously validated electronic blood pressure cuf f 
(Oklar Cuf f Model C02) that will be delivered to participants upon enrollment in the study . 
The blood pressure cuf f is capable of executing blood pressure measurements with minimal 
input from the user . Blood pressure is reported as systolic over diastolic, and the user will 
input these numbers into the application questionnaire.
Daily Steps
Daily steps will be assessed using communication between the Pro2col application and the 
user‚Äôs Apple Health or Google Fit application. Apple Health and Google Fit both collect 
daily step counts by way of accelerometry , gyroscopy , and global positioning systems (GPS) 
and these data will be transferred to and housed within the Pro2col application.
Depr ession 
Symptoms of depression will be assessed using the Patient Health Questionnaire-9 
(PHQ-9). This questionnaire is a previously validated tool that collects information about 
depression symptoms in users. The user answers nine questions relating to depression 
symptoms on a scale of 0-3, with 0 representing no issues at all, and 3 representing 
experiencing the symptom nearly every day. The user‚Äôs total score is a summation of their 
responses, and is scored as follows:
1-4 Minimal depression
5-9 Mild depression
10-14 Moderate depression
15-19 Moderately severe depression
20-27 Severe depression
Importantly , users who score ‚â• 10 arbitrary units on the PHQ-9 during baseline testing will 
fail to continue being eligible for the study . In this instance, a study staff member will 
contact the individual, explain the reasoning, and thank the subject for their time. Due to the 
remote nature of this study , it is impossible to partner with a mental health clinic for subject 
referrals. Subjects will be encouraged to speak with their primary care physician if they are 
30
concerned about their score. An email script will be crafted to provide further information 
for this instance.
Quality of Life
Quality of life will be assessed by the previously validated 36-item Short Form survey 
(SF-36). The SF-36 houses a number of questions pertaining to various factors of quality of 
life. Subjects will answer questions in a variety of manners, from simple ‚Äúyes‚Äù or ‚Äúno‚Äù 
responses to Likert-adjacent scaled responses that allow the subject to select the answer that 
best corresponds to their attitudes and beliefs. The scoring instructions for the SF-36 can be 
accessed in the .pdf linked 
her e
.
31